68Gallium DOTANOC-PET imaging in lung carcinoids: impact on patients' management.
Authors
Lamarca, AngelaPritchard, D Mark
Westwood, Thomas D
Papaxoinis, Georgios
Nonaka, Daisuke
Vinjamuri, Sobhan
Valle, Juan W
Manoharan, Prakash
Mansoor, Was
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, ENETS Centre of Excellence, Manchester, UKIssue Date
2017-04-12
Metadata
Show full item recordCitation
68Gallium DOTANOC-PET imaging in lung carcinoids: impact on patients' management. 2017, NeuroendocrinologyJournal
NeuroendocrinologyDOI
10.1159/000472717PubMed ID
28399530Type
ArticleLanguage
enISSN
1423-0194ae974a485f413a2113503eed53cd6c53
10.1159/000472717
Scopus Count
Collections
Related articles
- [Carcinoids and 68Ga-DOTANOC PET/CT].
- Authors: Borghammer P, Arveschoug AK, Hjorthaug K, Kindt SE, Jakobsen KS
- Issue date: 2013 Jan 7
- Does 68Ga-DOTA-NOC-PET/CT impact staging and therapeutic decision making in pulmonary carcinoid tumors?
- Authors: Purandare NC, Puranik A, Agrawal A, Shah S, Kumar R, Jiwnani S, Karimundackal G, Pramesh CS, Rangarajan V
- Issue date: 2020 Oct
- 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
- Authors: Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, Montini GC, Tomassetti P, Paganelli G, Fanti S
- Issue date: 2010 May
- Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid.
- Authors: Lococo F, Perotti G, Cardillo G, De Waure C, Filice A, Graziano P, Rossi G, Sgarbi G, Stefanelli A, Giordano A, Granone P, Rindi G, Versari A, Rufini V
- Issue date: 2015 Mar
- Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
- Authors: Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME
- Issue date: 2013 Mar